Secondary cytoreduction for relapsed ovarian cancer

Affiliations

¹ Medical Oncology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
² Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome 00168, Italy. Electronic address: elenagiudice6@gmail.com.

Comment

Giovanni Maria Iannantuono et al. Lancet Oncol. 2021 Jun.

. 2021 Jun;22(6):e232.

doi: 10.1016/S1470-2045(21)00277-1.

¹ Medical Oncology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
² Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome 00168, Italy. Electronic address: elenagiudice6@gmail.com.

No abstract available

Conflict of interest statement

We declare no competing interests.

Secondary cytoreduction for relapsed ovarian cancer - Authors' reply.
Chen Y, Shi T, Liu J, Zhu J, Zang R. Chen Y, et al. Lancet Oncol. 2021 Jun;22(6):e233. doi: 10.1016/S1470-2045(21)00294-1. Lancet Oncol. 2021. PMID: 34087142 No abstract available.

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, Jia H, Huang X, Cai Y, Yin S, Jiang R, Tian W, Gao W, Liu J, Yang H, Cheng X, Zang R. Shi T, et al. Lancet Oncol. 2021 Apr;22(4):439-449. doi: 10.1016/S1470-2045(21)00006-1. Epub 2021 Mar 8. Lancet Oncol. 2021. PMID: 33705695 Clinical Trial.